Genprex, Inc. 8-K

What Happened

• Genprex, Inc. filed a Form 8‑K (Dec 23, 2025) reporting it received a Nasdaq deficiency notice and later a temporary exception, and that it believes recent financings have raised its stockholders’ equity above Nasdaq’s minimum requirement. Nasdaq’s Listing Qualifications Staff initially notified the company of noncompliance on August 19, 2025. The Nasdaq Hearings Panel granted an exception on November 25, 2025, giving the company until December 31, 2025 to demonstrate long‑term compliance.

Key Details

• The company cites proceeds from registered direct offerings that closed on October 24, 2025 and October 29, 2025.
• Additional proceeds came from an “at‑the‑market” (ATM) offering conducted with H.C. Wainwright & Co. and from draws on an equity line with Lincoln Park Capital, LLC.
• As of the 8‑K filing date, Genprex believes its stockholders’ equity exceeds Nasdaq’s Listing Rule 5550(b)(1) minimum; however, the Nasdaq Panel has not yet made a final determination.
• The company included standard forward‑looking statement cautionary language about risks and uncertainty.

Why It Matters

• For investors, the filing signals that Genprex raised capital and believes it has addressed the specific Nasdaq equity deficiency, which is a key step to keep its common stock listed on the Nasdaq Capital Market.
• Listing status remains uncertain until the Nasdaq Panel confirms compliance; if the Panel does not find the company compliant, continued listing could be at risk.
• Investors should watch for any further Nasdaq determinations and subsequent company disclosures about final compliance, additional financings, or changes to listing status.